SG11202008177WA - Compstatin analogues and their medical uses - Google Patents

Compstatin analogues and their medical uses

Info

Publication number
SG11202008177WA
SG11202008177WA SG11202008177WA SG11202008177WA SG11202008177WA SG 11202008177W A SG11202008177W A SG 11202008177WA SG 11202008177W A SG11202008177W A SG 11202008177WA SG 11202008177W A SG11202008177W A SG 11202008177WA SG 11202008177W A SG11202008177W A SG 11202008177WA
Authority
SG
Singapore
Prior art keywords
medical uses
compstatin analogues
compstatin
analogues
medical
Prior art date
Application number
SG11202008177WA
Inventor
Pernille Tofteng Shelton
Jacob Ulrik Fog
Jens Kvist Madsen
Original Assignee
Zp Spv 3 K/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/S filed Critical Zp Spv 3 K/S
Publication of SG11202008177WA publication Critical patent/SG11202008177WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11202008177WA 2018-02-27 2019-02-26 Compstatin analogues and their medical uses SG11202008177WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18158834 2018-02-27
EP18214949 2018-12-20
PCT/EP2019/054685 WO2019166411A1 (en) 2018-02-27 2019-02-26 Compstatin analogues and their medical uses

Publications (1)

Publication Number Publication Date
SG11202008177WA true SG11202008177WA (en) 2020-09-29

Family

ID=65516661

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008177WA SG11202008177WA (en) 2018-02-27 2019-02-26 Compstatin analogues and their medical uses

Country Status (17)

Country Link
US (1) US11965039B2 (en)
EP (1) EP3759120A1 (en)
JP (1) JP2021515759A (en)
KR (1) KR20200135797A (en)
CN (1) CN112041330A (en)
AU (1) AU2019228639A1 (en)
BR (1) BR112020017385A2 (en)
CA (1) CA3091993A1 (en)
CL (1) CL2020002197A1 (en)
CO (1) CO2020011027A2 (en)
IL (1) IL276877A (en)
MX (1) MX2020008902A (en)
PE (1) PE20201254A1 (en)
RU (1) RU2020128624A (en)
SG (1) SG11202008177WA (en)
TW (1) TW202000686A (en)
WO (1) WO2019166411A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019247467B2 (en) 2018-04-06 2023-01-19 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
EP4272751A3 (en) * 2019-08-27 2024-02-14 Zp Spv 3 K/S Compstatin analogues and their medical uses
EP4182023A1 (en) * 2020-07-16 2023-05-24 Zp Spv 3 K/S Inhibitors of complement factor c3 and their medical uses
EP4281464A1 (en) 2021-01-20 2023-11-29 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2024110878A1 (en) * 2022-11-24 2024-05-30 Amyndas Pharmaceuticals Us Llc Compstatin analogs for vector-based therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
CZ295838B6 (en) 1996-09-09 2005-11-16 Zealand Pharma A/S Process for preparing peptides
AU4648197A (en) * 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
BR0009040A (en) 1999-03-17 2001-12-18 Novo Nordisk As Method for acylating an amino group of a peptide or a protein, and, compound
ES2373649T3 (en) 2002-09-20 2012-02-07 The Trustees Of The University Of Pennsylvania COMPSTATINE ANALOGS WITH IMPROVED ACTIVITY.
CN101325963B (en) 2005-10-08 2016-01-27 博泰迪亚制药公司 For compstatin and its analog of eye disorders
EP2377877B1 (en) * 2005-11-28 2018-03-28 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
US8442776B2 (en) 2007-06-08 2013-05-14 The Trustees Of The University Of Pennsylvania Structure of compstatin-C3 complex and use for rational drug design
CN102458438A (en) * 2009-05-01 2012-05-16 宾夕法尼亚州大学理事会 Modified compstatin with peptide backbone and c-terminal modifications
WO2012040259A2 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
EP2753636B1 (en) * 2011-09-07 2019-10-23 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
WO2014078734A2 (en) 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US9512180B2 (en) * 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
EP4272751A3 (en) * 2019-08-27 2024-02-14 Zp Spv 3 K/S Compstatin analogues and their medical uses

Also Published As

Publication number Publication date
WO2019166411A1 (en) 2019-09-06
CL2020002197A1 (en) 2021-03-05
US11965039B2 (en) 2024-04-23
PE20201254A1 (en) 2020-11-16
CA3091993A1 (en) 2019-09-06
KR20200135797A (en) 2020-12-03
RU2020128624A (en) 2022-03-28
TW202000686A (en) 2020-01-01
JP2021515759A (en) 2021-06-24
MX2020008902A (en) 2020-12-03
AU2019228639A1 (en) 2020-09-17
EP3759120A1 (en) 2021-01-06
CN112041330A (en) 2020-12-04
CO2020011027A2 (en) 2020-12-10
IL276877A (en) 2020-10-29
US20230192770A1 (en) 2023-06-22
BR112020017385A2 (en) 2020-12-15

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
IL276877A (en) Compstatin analogues and their medical uses
IL290858A (en) Compstatin analogues and their medical uses
IL253872B (en) Non-natural semaphorins 3 and their medical use
ZA201907833B (en) Heteroarylphenylaminoquinolines and analogues
GB201711749D0 (en) Cyclosporin analogues and uses thereof
HK1255425A1 (en) Application member and medical instrument
SG11202006669RA (en) Peptides and uses thereof
IL257559B (en) Hydroxytriazine compound and medical use thereof
GB201709840D0 (en) Methods and medical uses
EP3735277C0 (en) Medical materials and devices
EP3578566C0 (en) Biocidal peptide and preparation based thereon
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
GB201714409D0 (en) Oligonucleotides and analogues thereof
GB2600270B (en) Polymer-comrprising medical devices and uses thereof
EP3947418C0 (en) Peptides and use thereof
EP3903741C0 (en) Bio-coating and implant
GB2561945B (en) Tissue stain and use thereof
GB201906914D0 (en) Substituted naphtahlene diimdes and their use
GB201807050D0 (en) Medical uses
GB201714510D0 (en) Prothesis and othosis
GB201708081D0 (en) Surgical assembly and system
GB201802743D0 (en) Medicament and use thereof
IL292646A (en) Pharmaceutical combination and use thereof
GB201806133D0 (en) Methods and medical uses